BMS-906024

Phase 1Small molecule

Bristol-Myers Squibb

BMS-906024 is one of 46 small molecule programs targeting Lymphoblastic Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaActive, not recruiting

Lymphoblastic LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Lymphoblastic Lymphoma

#DrugCompanyPhaseTrials

Cytosar

Teva

Approved

6 2

Trexall

Alnylam Pharmaceuticals

Approved

6 3

Oncovin

Eli Lilly

Approved

3 4

Tabloid

Akero Therapeutics

Approved

6 5

Cytoxan

BBaxter Healthcare Corporation

Approved

6 6

Purinethol

SStason

Approved

5 7

Ninlaro

Fludara

Cerubidine

HHikma Pharmaceuticals LLC

Approved

3 10

Dacogen

Sun Pharma

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01292655·94 enrolled

Metastatic Solid Tumors1 trial

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01653470·141 enrolled

Lymphoblastic Lymphoma1 trial

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01363817·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BMS-906024. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-906024 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-906024. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bristol-Myers Squibb

BMS-906024

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Metastatic Solid Tumors1 trial

Lymphoblastic Lymphoma1 trial

References

Drug Info

Quick Facts

Related News